Survival Up With Daratumumab in Relapsed Multiple Myeloma

Share this content:
Survival Up With Daratumumab in Relapsed Multiple Myeloma
Survival Up With Daratumumab in Relapsed Multiple Myeloma

TUESDAY, Aug. 24, 2016 (HealthDay News) -- Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in the Aug. 25 issue of the New England Journal of Medicine.

Antonio Palumbo, M.D., from the University of Turin in Italy, and colleagues conducted a phase 3 trial involving 498 patients with relapsed or relapsed and refractory multiple myeloma. Participants were randomized to receive bortezomib and dexamethasone alone or in combination with daratumumab.

The researchers found that the rate of progression-free survival was significantly higher in the daratumumab group than the control group in a prespecified interim analysis; the 12-month rate of progression-free survival was 60.7 and 26.9 percent in the daratumumab and control groups, respectively. The median progression-free survival was not reached in the daratumumab group and was 7.2 months in the control group after a median follow-up period of 7.4 months (hazard ratio, 0.39; P < 0.001). The daratumumab group had higher rates of overall response (82.9 versus 63.2 percent; P < 0.001), very good partial response or better (59.2 versus 29.1 percent; P < 0.001), and complete response or better (19.2 versus 9.0 percent; P = 0.001).

"Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than bortezomib and dexamethasone alone," the authors write.

The study was funded by Janssen Research and Development, the manufacturer of daratumumab.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Warns of Possible Heart Risks Linked to Clarithromycin

FDA Warns of Possible Heart Risks Linked to ...

Agency advising doctors to consider prescribing other antibiotics to patients with coronary heart disease

Artificial Intelligence May Help Prevent Physician Burnout

Artificial Intelligence May Help Prevent Physician Burnout

Many potential uses for AI, including improving searches and documentation, selecting treatment

Benzodiazepine Use Declining in Older Adults

Benzodiazepine Use Declining in Older Adults

Findings based on assessment of incidence, prevalence of use in three countries from 2010-2016

is free, fast, and customized just for you!

Already a member?

Sign In Now »